Treace Medical Concepts Reports Third Quarter 2024 Financial Results
Revenue of $45.1 million in third quarter 2024 increased 11% over same period in 2023 Third quarter 2024 net loss was ($15.4) million compared to ($17.5) million for same period in 2023. Adjusted ...
Treace Comments on CMS’ 2025 Final Rule for Hospital Outpatient and ASC Settings
Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot ...
Treace Enters High Volume Osteotomy Market with Nanoplasty™ 3D Minimally Invasive Bunion Correction™ Procedure
Positions Treace to Significantly Increase Penetration into Overall Bunion Market and Expand Surgeon Customer BasePONTE VEDRA, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc.